Critical window hypothesis of hormone therapy and cognition: A scientific update on clinical studies

Menopause

Volumn 20, Issue 6, 2013, Pages 695-709

  Maki, Pauline M ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Cognition; Dementia; Estrogen; Memory; Menopause; Neuroimaging.

Indexed keywords

CONJUGATED ESTROGEN; ESTROGEN; GESTAGEN; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ALZHEIMER DISEASE; CLINICAL STUDY; COGNITION; ESTROGEN THERAPY; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HIPPOCAMPUS; HUMAN; HYPOTHESIS; MENSTRUAL CYCLE; MENTAL PERFORMANCE; NEUROIMAGING; NEUROLOGIC EXAMINATION; OBSERVATIONAL METHOD; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; THERAPY EFFECT; TREATMENT DURATION; VERBAL MEMORY;

AGE FACTORS; AGED; AGING; ALZHEIMER DISEASE; BRAIN; COGNITION; COGNITION DISORDERS; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MEMORY; MENOPAUSE; NEUROIMAGING; POSITRON-EMISSION TOMOGRAPHY; PROGESTINS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TIME FACTORS; VERBAL LEARNING;

EID: 84879140782     PISSN: 10723714     EISSN: 15300374     Source Type: Journal    
DOI: 10.1097/gme.0b013e3182960cf8     Document Type: Review

References (107)

1. Murphy SL, Xu J, Kochanek KD. Deaths: Preliminary data for 2010. Natl Vital Stat Rep 2012;61.
2. Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA. Alzheimer disease in the US population: Prevalence estimates using the 2000 census. Arch Neurol 2003;60:1119-1122.
3. Kung H-S, Hoyert DL, Xu J, Murphy SL. Deaths: Final data for 2005. CDC Natl Vital Stat Rep 2008;56:1-120.
4. Moschetti K, Cummings PL, Sorvillo F, Kuo T. Burden of Alzheimer's disease-related mortality in the United States, 1999-2008. J Am Geriatr Soc 2012;60:1509-1514.
5. Andersen K, Launer LJ, Dewey ME, et al. Gender differences in the incidence of AD and vascular dementia: The EURODEM Studies. EURODEM Incidence Research Group. Neurology 1999;53:1992-1997.
6. Alzheimer'sAssociation. Changing the Trajectory of Alzheimer's Disease: A National Imperative. Chicago, IL: Alzheimer's Association; 2010.
7. Marder K, Sano M. Estrogen to treat Alzheimer's disease: Too little, too late? So what's a woman to do? Neurology 2000;54:2035-2037.
8. Resnick SM, Henderson VW. Hormone therapy and risk of Alzheimer disease: A critical time. JAMA 2002;288:2170-2172
9. Shumaker S, Legault C, Kuller L, et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA 2004;291:2947-2958.
10. Shumaker S, Legault C, Rapp S, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: The Women's Health Initiative Memory Study: A randomized controlled trial. JAMA 2003;289:2651-2662.
11. Heyman A, Wilkinson WE, Stafford JA, Helms MJ, Sigmon AH, Weinberg T. Alzheimer's disease: A study of epidemiological aspects. Ann Neurol 1984;15:335-341.
12. Amaducci LA, Fratiglioni L, Rocca WA, et al. Risk factors for clinically diagnosed Alzheimer's disease: A case-control study of an Italian population. Neurology 1986;36:922-931.
13. Broe GA, Henderson AS, Creasey H, et al. A case-control study of Alzheimer's disease in Australia. Neurology 1990;40:1698-1707.
14. Graves AB, White E, Koepsell TD, et al. A case-control study of Alzheimer's disease. Ann Neurol 1990;28:766-774.
15. Mortel KF, Meyer JS. Lack of postmenopausal estrogen replacement therapy and the risk of dementia. J Neuropsychiatry 1994;7:334-337.
16. Baldereschi M, Di Carlo A, Lepore V, et al. Estrogen-replacement therapy and Alzheimer's disease in the Italian Longitudinal Study on Aging. Neurology 1998;50:996-1002.
17. Harwood DG, Barker WW, Loewenstein DA, et al. A cross-ethnic analysis of risk factors for AD in white Hispanics and white non-Hispanics. Neurology 1999;52:551-556.
18. Slooter AJ, Bronzova J, Witteman JC, Van Broeckhoven C, Hofman A, van Duijn CM. Estrogen use and early onset Alzheimer's disease: A populationbased study. J Neurol Neurosurg Psychiatry 1999;67:779-781.
19. Henderson VW, Benke KS, Green RC, Cupples LA, Farrer LA. Postmenopausal hormone therapy and Alzheimer's disease risk: Interaction with age. J Neurol Neurosurg Psychiatry 2005;76:103-105.
20. Brenner DE, Kukull WA, Stergachis A, et al. Postmenopausal estrogen replacement therapy and the risk of Alzheimer's disease: A populationbased case-control study. Am J Epidemiol 1994;140:262-267.
21. Henderson VW, Paganini-Hill A, Emanuel CK, Dunn ME, Buckwalter JG. Estrogen replacement therapy in older women. Comparisons between Alzheimer's disease cases and nondemented control subjects. Arch Neurol 1994;51:896-900.
22. Paganini-Hill A, Henderson VW. Estrogen replacement therapy and risk of Alzheimer disease. Arch Intern Med 1996;156:2213-2217.
23. Waring SC, Rocca WA, Petersen RC, O'Brien PC, Tangalos EG, Kokmen E. Postmenopausal estrogen replacement therapy and risk of AD: A population-based study. Neurology 1999;52:965-970.
24. Seshadri S, Zornberg GL, Derby LE, Myers MW, Jick H, Drachman DA. Postmenopausal estrogen replacement therapy and the risk of Alzheimer disease. Arch Neurol 2001;58:435-440.
25. Tang MX, Jacobs D, Stern Y, et al. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet 1996; 348:429-432.
26. Kawas C, Resnick S, Morrison A, et al. A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: The Baltimore Longitudinal Study of Aging. Neurology 1997;48:1517-1521.
27. Zandi PP, Carlson MC, Plassman BL, et al. Hormone replacement therapy and incidence of Alzheimer disease in older women: The Cache County Study. JAMA 2002;288:2123-2129.
28. Shao H, Breitner JC, Whitmer RA, et al. Hormone therapy and Alzheimer disease dementia: New findings from the Cache County Study. Neurology 2012;79:1846-1852.
29. Yaffe K, Sawaya G, Lieberburg I, Grady D. Estrogen therapy in postmenopausal women: Effects on cognitive function and dementia. JAMA 1998;279:688-695.
30. Hogervorst E, Williams J, Budge M, Riedel W, Jolles J. The nature of the effect of female gonadal hormone replacement therapy on cognitive function in post-menopausal women: A meta-analysis. Neuroscience 2000;101:485-512.
31. LeBlanc ES, Janowsky J, Chan BK, Nelson HD. Hormone replacement therapy and cognition: Systematic review and meta-analysis. JAMA 2001;285:1489-1499.
32. Nelson HD, Humphrey LL, Nygren P, Teutsch SM, Allan JD. Postmenopausal hormone replacement therapy: Scientific review. JAMA 2002;288:872-881.
33. Wang PN, Liao SQ, Liu RS, et al. Effects of estrogen on cognition, mood, and cerebral blood flow in AD: A controlled study. Neurology 2000;54:2061-2066.
34. Mulnard RA, Cotman CW, Kawas C, et al. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: A randomized controlled trial. Alzheimer's Disease Cooperative Study. JAMA 2000; 283:1007-1015.
35. Henderson VW, Paganini-Hill A, Miller BL, et al. Estrogen for Alzheimer's disease in women: Randomized, double-blind, placebocontrolled trial. Neurology 2000;54:295-301.
36. Marder K, Tang MX, Alfaro B, et al. Postmenopausal estrogen use and Parkinson's disease with and without dementia. Neurology 1998;50: 1141-1143.
37. Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA 1997;277:813-817.
38. Wassertheil-Smoller S, Hendrix SL, Limacher M, et al. Effect of estrogen plus progestin on stroke in postmenopausal women: The Women's Health Initiative: A randomized trial. JAMA 2003;289:2673-2684.
39. Coker LH, Hogan PE, Bryan NR, et al. Postmenopausal hormone therapy and subclinical cerebrovascular disease: The WHIMS-MRI Study. Neurology 2009;72:125-134.
40. Resnick SM, Espeland MA, Jaramillo SA, et al. Postmenopausal hormone therapy and regional brain volumes: The WHIMS-MRI Study. Neurology 2009;72:135-142.
41. Espeland MA, Tindle HA, Bushnell CA, et al. Brain volumes, cognitive impairment, and conjugated equine estrogens. J Gerontol A Biol Sci Med Sci 2009;64:1243-1250.
42. Whitmer RA, Quesenberry CP, Zhou J, Yaffe K. Timing of hormone therapy and dementia: The critical window theory revisited. Ann Neurol 2011;69:163-169.
43. Yesufu A, Bandelow S, Hogervorst E. Meta-analyses of the effect of hormone treatment on cognitive function in postmenopausal women. Womens Health (Lond) 2007;3:173-194.
44. Linn RT, Wolf PA, Bachman DL, et al. The Fpreclinical phase-of probable Alzheimer's disease. A 13-year prospective study of the Framingham cohort. Arch Neurol 1995;52:485-490.
45. Tierney MC, Yao C, Kiss A, McDowell I. Neuropsychological tests accurately predict incident Alzheimer disease after 5 and 10 years. Neurology 2005;64:1853-1859.
46. Blacker D, Lee H, Muzikansky A, et al. Neuropsychological measures in normal individuals that predict subsequent cognitive decline. Arch Neurol 2007;64:862-871.
47. Kramer J, Delis D, Daniel M. Sex differences in verbal learning. J Clin Psychol 1988;44:907-915.
48. Kramer JH, Delis DC, Kaplan E, O'Donnell L, Prifitera A. Developmental sex differences in verbal learning. Neuropsychology 1997;11: 577-584.
49. Greendale GA, Huang MH, Wight RG, et al. Effects of the menopause transition and hormone use on cognitive performance in midlife women. Neurology 2009;72:1850-1857.
50. Weber MT, Rubin LH, Maki PM. Cognition in perimenopause: The effect of transition stage. Menopause 2013;20:511-517.
51. Resnick SM, Coker LH, Maki PM, Rapp SR, Espeland MA, Shumaker SA. The Women's Health Initiative Study of Cognitive Aging (WHISCA): A randomized clinical trial of the effects of hormone therapy on age-associated cognitive decline. Clin Trials 2004;1:440-450.
52. Resnick SM, Maki PM, Rapp SR, et al. Effects of combination estrogen plus progestin hormone treatment on cognition and affect. J Clin Endocrinol Metab 2006;91:1802-1810.
53. Resnick SM, Espeland MA, An Y, et al. Effects of conjugated equine estrogens on cognition and affect in postmenopausal women with prior hysterectomy. J Clin Endocrinol Metab 2009;94:4152-4161.
54. Kang JH, Weuve J, Grodstein F. Postmenopausal hormone therapy and risk of cognitive decline in community-dwelling aging women. Neurology 2004;63:101-107.
55. Ryan J, Carriere I, Scali J, et al. Characteristics of hormone therapy, cognitive function, and dementia: The prospective 3C Study. Neurology 2009;73:1729-1737.
56. Khoo SK, O'Neill S, Byrne G, King R, Travers C, Tripcony L. Postmenopausal hormone therapy and cognition: Effects of timing and treatment type. Climacteric 2010;13:259-264.
57. Kang JH, Grodstein F. Postmenopausal hormone therapy, timing of initiation, APOE and cognitive decline. Neurobiol Aging 2012;33:1129-1137.
58. MacLennan AH, Henderson VW, Paine BJ, et al. Hormone therapy, timing of initiation, and cognition in women aged older than 60 years: The REMEMBER pilot study. Menopause 2006;13:28-36.
59. Maki PM. A systematic review of clinical trials of hormone therapy on cognitive function: Effects of age at initiation and progestin use. Ann N Y Acad Sci 2005;1052:182-197.
60. Maki PM, Dumas J. Mechanisms of action of estrogen in the brain: Insights from human neuroimaging and psychopharmacologic studies. Semin Reprod Med 2009;27:250-259.
61. Hackman BW, Galbraith D. Replacement therapy and piperazine oestrone sulphate (FHarmogen-) and its effect on memory. Curr Med Res Opin 1976;4:303-306.
62. Sherwin BB. Estrogen and/or androgen replacement therapy and cognitive functioning in surgically menopausal women. Psychoneuroendocrinology 1988;13:345-357.
63. Phillips SM, Sherwin BB. Effects of estrogen on memory function in surgically menopausal women. Psychoneuroendocrinology 1992;17: 485-495.
64. Shaywitz SE, Naftolin F, Zelterman D, et al. Better oral reading and short-term memory in midlife, postmenopausal women taking estrogen. Menopause 2003;10:420-426.
65. Dunkin J, Rasgon N, Wagner-Steh K, David S, Altshuler L, Rapkin A. Reproductive events modify the effects of estrogen replacement therapy on cognition in healthy postmenopausal women. Psychoneuroendocrinology 2005;30:284-296.
66. LeBlanc ES, Neiss MB, Carello PE, Samuels MH, Janowsky JS. Hot flashes and estrogen therapy do not influence cognition in early menopausal women. Menopause 2007;14:191-202.
67. Joffe H, Hall JE, Gruber S, et al. Estrogen therapy selectively enhances prefrontal cognitive processes: A randomized, double-blind, placebocontrolled study with functional magnetic resonance imaging in perimenopausal and recently postmenopausal women. Menopause 2006; 13:411-422.
68. Rocca WA, Bower JH, Maraganore DM, et al. Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause. Neurology 2007;69:1074-1083.
69. Wolf OT, Kudielka BM, Hellhammer DH, Torber S, McEwen BS, Kirschbaum C. Two weeks of transdermal estradiol treatment in postmenopausal elderly women and its effect on memory and mood: Verbal memory changes are associated with the treatment induced estradiol levels. Psychoneuroendocrinology 1999;24:727-741.
70. Yaffe K, Vittinghoff E, Ensrud KE, et al. Effects of ultra-low-dose transdermal estradiol on cognition and health-related quality of life. Arch Neurol 2006;63:945-950.
71. Almeida OP, Lautenschlager NT, Vasikaran S, Leedman P, Gelavis A, Flicker L. A 20-week randomized controlled trial of estradiol replacement therapy for women aged 70 years and older: Effect on mood, cognition and quality of life. Neurobiol Aging 2006;27:141-149.
72. Pefanco MA, Kenny AM, Kaplan RF, et al. The effect of 3-year treatment with 0.25 mg/day of micronized 17A-estradiol on cognitive function in older postmenopausal women. J Am Geriatr Soc 2007;55:426-431.
73. Schiff R, Bulpitt CJ, Wesnes KA, Rajkumar C. Short-term transdermal estradiol therapy, cognition and depressive symptoms in healthy older women. A randomised placebo controlled pilot cross-over study. Psychoneuroendocrinology 2005;30:309-315.
74. Toran-Allerand CD. Reply to FHormone in the hot seat. Nat Med 2006;12:379-380.
75. Rapp PR, Morrison JH, Roberts JA. Cyclic estrogen replacement improves cognitive function in aged ovariectomized rhesus monkeys. J Neurosci 2003;23:5708-5714.
76. Ohm DT, Bloss EB, Janssen WG, et al. Clinically relevant hormone treatments fail to induce spinogenesis in prefrontal cortex of aged female rhesus monkeys. J Neurosci 2012;32:11700-11705.
77. Tang Y, Janssen WG, Hao J, et al. Estrogen replacement increases spinophilin-immunoreactive spine number in the prefrontal cortex of female rhesus monkeys. Cereb Cortex 2004;14:215-223.
78. Linzmayer L, Semlitsch HV, Saletu B, et al. Double-blind, placebocontrolled psychometric studies on the effects of a combined estrogenprogestin regimen versus estrogen alone on performance, mood and personality of menopausal syndrome patients. Arzneimittelforschung 2001;51:238-245.
79. Wolf OT, Heinrich AB, Hanstein B, Kirschbaum C. Estradiol or estradiol/progesterone treatment in older women: No strong effects on cognition. Neurobiol Aging 2005;26:1029-1033.
80. Maki PM, Gast MJ, Vieweg AJ, Burriss SW, Yaffe K. Hormone therapy in menopausal women with cognitive complaints: A randomized, doubleblind trial. Neurology 2007;69:1322-1330.
81. Maki PM, Rubin LH, Fornelli D, et al. Effects of botanicals and combined hormone therapy on cognition in postmenopausal women. Menopause 2009;16:1167-1177.
82. Alhola P, Tuomisto H, Saarinen R, Portin R, Kalleinen N, Polo-Kantola P. Estrogen + progestin therapy and cognition: A randomized placebo-controlled double-blind study. J Obstet Gynaecol Res 2010; 36:796-802.
83. Binder EF, Schechtman KB, Birge SJ, Williams DB, Kohrt WM. Effects of hormone replacement therapy on cognitive performance in elderly women. Maturitas 2001;38:137-146.
84. Grady D, Yaffe K, Kristof M, Lin F, Richards C, Barrett-Connor E. Effect of postmenopausal hormone therapy on cognitive function: The Heart and Estrogen/progestin Replacement Study. Am J Med 2002; 113:543-548.
85. Tierney MC, Oh P, Moineddin R, et al. A randomized double-blind trial of the effects of hormone therapy on delayed verbal recall in older women. Psychoneuroendocrinology 2009;34:1065-1074.
86. Resnick SM, Maki PM, Golski S, Kraut MA, Zonderman AB. Effects of estrogen replacement therapy on PET cerebral blood flow and neuropsychological performance. Horm Behav 1998;34:171-182.
87. Maki PM, Resnick SM. Longitudinal effects of estrogen replacement therapy on PET cerebral blood flow and cognition. Neurobiol Aging 2000;21:373-383.
88. Mosconi L, Tsui WH, De Santi S, et al. Reduced hippocampal metabolism in MCI and AD: Automated FDG-PET image analysis. Neurology 2005;64:1860-1867.
89. Shaywitz SE, Shaywitz BA, Pugh KR, et al. Effect of estrogen on brain activation patterns in postmenopausal women during working memory tasks. JAMA 1999;281:1197-1202.
90. Berent-Spillson A, Persad CC, Love T, et al. Early menopausal hormone use influences brain regions used for visual working memory. Menopause 2010;17:692-699.
91. Maki PM, Dennerstein L, Clark M, et al. Perimenopausal use of hormone therapy is associated with enhanced memory and hippocampal function later in life. Brain Res 2011;1379:232-243.
92. Craig MC, Fletcher PC, Daly EM, et al. Gonadotropin hormone releasing hormone agonists alter prefrontal function during verbal encoding in young women. Psychoneuroendocrinology 2007;32:1116-1127.
93. Craig MC, Fletcher PC, Daly EM, et al. Reversibility of the effects of acute ovarian hormone suppression on verbal memory and prefrontal function in pre-menopausal women. Psychoneuroendocrinology 2008; 33:1426-1431.
94. Eberling JL, Wu C, Haan MN, Mungas D, Buonocore M, Jagust WJ. Preliminary evidence that estrogen protects against age-related hippocampal atrophy. Neurobiol Aging 2003;24:725-732.
95. Erickson KI, Voss MW, Prakash RS, Chaddock L, Kramer AF. A crosssectional study of hormone treatment and hippocampal volume in postmenopausal women: Evidence for a limited window of opportunity. Neuropsychology 2010;24:68-76.
96. Lord C, Buss C, Lupien SJ, Pruessner JC. Hippocampal volumes are larger in postmenopausal women using estrogen therapy compared to past users, never users and men: A possible window of opportunity effect. Neurobiol Aging 2008;29:95-101.
97. Brinton RD. Investigative models for determining hormone therapyY induced outcomes in brain: Evidence in support of a healthy cell bias of estrogen action. Ann N Y Acad Sci 2005;1052:57-74.
98. Espeland M, Rapp S, Shumaker S, et al. Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study. JAMA 2004;291:2959-2968.
99. Yaffe K, Krueger K, Cummings SR, et al. Effect of raloxifene on prevention of dementia and cognitive impairment in older women: The Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial. Am J Psychiatry 2005;162:683-690.
100. Clarkson TB, Melendez GC, Appt SE. Timing hypothesis for postmenopausal hormone therapy: Its origin, current status, and future. Menopause 2013;20:342-353.
101. Salpeter SR, Walsh JM, Greyber E, Salpeter EE. Brief report: Coronary heart disease events associated with hormone therapy in younger and older women. A meta-analysis. J Gen Intern Med 2006;21:363-366.
102. LaCroix AZ, Chlebowski RT, Manson JE, et al. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: A randomized controlled trial. JAMA 2011; 305:1305-1314.
103. Kivipelto M, Helkala EL, Laakso MP, et al. Apolipoprotein E epsilon4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease. Ann Intern Med 2002;137:149-155.
104. Kivipelto M, Ngandu T, Fratiglioni L, et al. Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease. Arch Neurol 2005;62:1556-1560.
105. Whitmer RA, Sidney S, Selby J, Johnston SC, Yaffe K. Midlife cardiovascular risk factors and risk of dementia in late life. Neurology 2005;64:277-281.
106. Kivipelto M, Helkala EL, Laakso MP, et al. Midlife vascular risk factors and Alzheimer's disease in later life: Longitudinal, population based study. BMJ 2001;322:1447-1451.
107. Solomon A, Kivipelto M, Wolozin B, Zhou J, Whitmer RA. Midlife serum cholesterol and increased risk of Alzheimer's and vascular dementia three decades later. Dement Geriatr Cogn Disord 2009; 28:75-80.